GSK planning to file belantamab mafodotin in multiple myeloma after positive Phase II study

LONDON, 23 Aug (APM) - GlaxoSmithKline on Friday reported positive Phase II results from a pivotal study for belantamab mafodotin in a certain type of blood cancer.
GSK said in its statement it is now on track to file the drug with regulatory authorities later this year.
The DREAMM-2 trial tested two doses of belantamab mafodotin in those with relapsed multiple myeloma who were refractory to an immunomodulatory drug, a proteasome inhibitor, and to treatment with an anti-CD38 antibody.
DREAMM-2 met its primary objective of demonstrating a clinically meaningful overall response rate with belantamab mafodotin in the patient population.
Dr Hal Barron, chief scientific officer and president of R&D at GSK, said: "I am pleased with the results of the DREAMM-2 study and excited about what these data could mean for patients with multiple myeloma who have exhausted other lines of treatment."
Belantamab mafodotin is an immuno-conjugate comprising a humanised anti-B cell maturation antigen monoclonal antibody.
GSK said it has planned a Phase III trial, known as DREAMM-3, which will pit the drug against Celgene's Imnovid (pomalidomide) plus low-dose dexamethasone in those with relapsed or refractory multiple myeloma.



Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations

Events coverage with a unique focus on Market Access & sustainability of healthcare systems

6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris

Ask for a Free trial and get access to the latest stories

Our coverage includes:
  • Health Care
  • Market Access
  • HTA – policies & practices
  • European medicine regulations
  • Drug safety issues
  • Pricing & Reimbursement
  • International medicines agencies

If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.


an initial 10 day temporary access of APM Health Europe.